Addressing the dense stromal barrier, it reveals that the interaction between cancer cell NRG1 and CAF ERBB3 activates the STAT3 pathway, leading to the “ERBB3 inhibitor + stromal metalloproteinase activator” strategy. Here, NRG1 is linked to cancer.